Authors: Gaborit, Benjamin, Vanhove, Bernard, Vibet, Marie-Anne, Le Thuaut, Aurélie, Lacombe, Karine, Dubee, Vincent, Ader, Florence, Ferre, Virginie, Vicaut, Eric, Orain, Jéremie, Le Bras, Morgane, Omnes, Anne, Berly, Laetitia, Jobert, Alexandra, Morineau-Le Houssine, Pascale, Botturi, Josien, Régis, Flet, Laurent, Degauque, Nicolas, Brouard, Sophie, Duvaux, Odile, Poinas, Raffi, François, Dailly, Guimard, Thomas, Braudeau, Cécile, Malvy, Denis, Faucher, Jean-François, Illes Hajnal, Gabriela, Vareil, Marc-Olivier, Roncato-Saberam, Mariam, Vacher, Biron, Charlotte, Lefebvre, Maeva, Gallot, Géraldine, Le Turnier, Paul, Deschanvres, Colin, Lecomte, Raphael, Chauveau, Marie, Lecompte, Anne-sophie, Grégoire, Matthieu, Bellouard, Ronan, Deslandes, Guillaume, Ouazene, Zineb, Bollens, Diane, Chiarabani, Thibault, Krause-Le Garrec, Jessica, Becker, Agathe, Chauvelot, Pierre, Conrad, Ferry, Tristan, Miailhes, Patrick, Pouderoux, Roux, Sandrine, Triffault-Fillit, Claire

Venue: Trials

Type: Publication

Abstract: Abstract Background Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages such as providing immediate immunity, consequently blunting an early pro-inflammatory pathogenic endogenous antibody response and lack of drug-drug interactions. By providing immediate immunity and inhibiting entry into cells, neutralizing antibody treatment is of interest for patient with COVID-19-induced moderate pne... (read more)

DOI: 10.1186/s13063-021-05132-9